Welcome to our dedicated page for Sophia Genetics Sa SEC filings (Ticker: SOPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SOPHiA GENETICS SA (Nasdaq: SOPH) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer. SOPHiA GENETICS files reports such as Form 20-F and Form 6-K with the U.S. Securities and Exchange Commission, offering detailed information on its financial condition, operations, and material announcements related to its AI-powered healthcare technology business.
Recent Form 6-K filings have included unaudited interim condensed consolidated financial statements, management’s discussion and analysis of financial condition and results of operations, and press releases covering quarterly results and business updates. These documents give investors insight into revenue trends, non-IFRS measures such as adjusted gross profit and adjusted EBITDA, geographic revenue breakdowns, and segment information that includes the SOPHiA DDM™ Platform and workflow equipment and services.
Through this page, users can review how SOPHiA GENETICS reports on topics such as platform usage, analysis volumes, regional performance, and capital structure. Filings may also reference warrant liabilities, credit agreements, and other financial instruments, along with discussions of constant currency revenue and other metrics used by management to evaluate performance.
Stock Titan enhances these filings with AI-powered summaries that explain key points in accessible language, helping readers understand complex sections of financial statements and management commentary. Users can quickly identify important themes in SOPHiA GENETICS’ 20-F annual reports, 6-K current reports, and other submissions, and then drill into the original documents for more detail.
In addition, this page offers convenient access to information relevant to governance and capital markets activity, such as exhibits attached to 6-Ks and references to registration statements. While SOPHiA GENETICS is not a U.S. domestic issuer and does not file Forms 10-K or 10-Q, its 20-F and 6-K filings serve a similar role for investors analyzing SOPH stock and the company’s AI-driven precision medicine platform.
SOPHiA GENETICS SA President Ross Muken reported two small open-market sales of Ordinary Shares to cover taxes from equity vesting. On April 10 and 13, 2026, he sold a total of 8,129 shares at weighted average prices around $4.69–$4.77 per share. A footnote explains these transactions were made to satisfy tax withholding obligations arising from restricted stock units that vested on April 2 and 3, 2026, and were executed under a pre-established Rule 10b5-1(c) trading plan, meaning they were not discretionary trades. Following the sales, he continues to hold 685,232 Ordinary Shares directly.
SOPHiA GENETICS SA Chief Medical Officer Philippe Menu reported small open-market sales of Ordinary Shares mainly to cover taxes from recent equity vesting. Across three transactions on April 10 and April 13, 2026, he sold a total of 8,125 shares at weighted-average prices around $4.68–$4.76 per share. The filing states these sales were made to satisfy tax withholding obligations tied to restricted stock units that vested on April 2 and 3, 2026 and were executed under a pre-established Rule 10b5-1(c) trading plan. After these transactions, Menu continues to hold 268,596 Ordinary Shares directly.
SOPHiA GENETICS SA Chief Executive Officer Jurgi Camblong reported routine tax-related share sales. He sold 2,800 Ordinary Shares on April 8 at a weighted average of $4.8404 and 1,950 shares on April 9 at a weighted average of $4.7404 in open‑market transactions.
Footnotes state these sales were made solely to satisfy tax withholding obligations tied to restricted stock units that vested on April 2 and 3, 2026, under a pre‑established Rule 10b5‑1 trading plan. After these transactions, he continues to hold 3,724,200 Ordinary Shares directly.
SOPHiA GENETICS SA president Ross Muken reported open-market sales of ordinary shares primarily to cover taxes from equity compensation. On April 8 and 9, 2026, he sold a total of 4,736 shares at weighted average prices of about $4.84 and $4.74 per share. The filing states these trades were executed under a pre-established Rule 10b5-1 trading plan and were made to satisfy tax withholding obligations tied to restricted stock units that vested earlier in April. After these sales, Muken still directly holds 693,361 ordinary shares, indicating the transactions represent a small portion of his overall position.
SOPHiA GENETICS SA Chief Scientific Officer Zhenyu Xu sold 4,736 Ordinary Shares of SOPH in open-market transactions. The sales occurred on April 8 and 9, 2026 at weighted average prices of about $4.84 and $4.74 per share.
According to the disclosure, these shares were sold to cover tax withholding obligations from restricted stock units that vested on April 2 and 3, 2026. The transactions were executed under a pre-established Rule 10b5-1 trading plan and are described as non-discretionary. After the sales, Xu directly held 640,216 Ordinary Shares.
SOPHiA GENETICS SA Chief Medical Officer Philippe Menu disposed of 4,731 Ordinary Shares in open-market sales tied to tax obligations. On April 8, he sold 2,800 shares at a weighted average of $4.8370, and on April 9 he sold 1,931 shares at a weighted average of $4.7393.
The footnotes state these sales were made to satisfy tax withholding obligations from restricted stock units that vested on April 2 and 3, 2026 and were executed under a pre-established Rule 10b5-1 trading plan, meaning they were not discretionary trades. After these transactions, Menu directly holds 276,721 Ordinary Shares.
SOPHiA GENETICS SA Chief People Officer Manuela Valente reported an open-market sale of 3,824 Ordinary Shares on April 8, 2026 at a weighted average price of $4.849 per share. According to the disclosure, the shares were sold to satisfy tax withholding obligations from restricted stock units that vested on April 2 and 3, 2026.
The filing states these sales were executed under a pre-established Rule 10b5-1 trading plan and are described as non-discretionary. After this transaction, Valente directly holds 215,451 Ordinary Shares of SOPHiA GENETICS SA.
SOPHiA GENETICS SA Chief Legal Officer Daan Van Well reported routine tax-related share sales. He sold a total of 4,849 Ordinary Shares in open-market transactions on April 8 and 9, 2026 at weighted average prices of $4.8452 and $4.7406 per share. According to the disclosure, these sales were made to satisfy tax withholding obligations from the vesting of restricted stock units under a pre-established Rule 10b5-1 trading plan and are not discretionary trades. After these transactions, he continues to hold 348,820 Ordinary Shares directly.
SOPHiA GENETICS SA Chief Financial Officer George Cardoza sold 1,403 ordinary shares of SOPH on April 8, 2026. The shares were sold in open-market transactions at a weighted average price of about $4.85 per share to cover tax withholding from recently vested restricted stock units.
According to the disclosure, these sales were made under a pre-established Rule 10b5-1 trading plan and are described as non-discretionary. After these transactions, Cardoza directly holds 291,458 ordinary shares, indicating the sale represents a small portion of his overall position.
Morgan Stanley Smith Barney LLC reported a Form 144 disclosing sale activity by a holder associated with SOPH. The filing lists restricted stock units (1 RSU) with an award date of 04/02/2026 and three 10b5-1 sale transactions totaling 5,707 shares executed on 03/19/2026, 04/06/2026, and 04/07/2026.